Raymond M. Paranal

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.

A. Redig, P. Jänne, M. Eck, 2017, Cancer research.

AWARD NUMBER: W81XWH-16-1-0106 TITLE: Fragment-Based Approaches to Enhance GTP Competitive KRAS G12C Inhibitors PRINCIPAL INVESTIGATOR: Kenneth Westover CONTRACTING ORGANIZATION: University of Texas Southwestern Medical Center

David A. Scott, Kwok-Kin Wong, N. Gray, 2018 .

Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.

P. Jänne, N. Farag, K. Abouzid, 2016, Bioorganic & medicinal chemistry.

KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

Haiyun Wang, John C. Hunter, Shuai Li, 2018, Cell.

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer

G. Daley, C. Paweletz, P. Jänne, 2021, Science Translational Medicine.

Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.

David A. Scott, P. Jänne, Kwok-Kin Wong, 2017, Cell chemical biology.

Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance

L. Wood, R. Hruban, J. Eshleman, 2022, eLife.

Functional CDKN 2 A assay identifies frequent deleterious alleles misclassified as variants 1 of uncertain significance 2 3

L. Wood, R. Hruban, A. Klein, 2022 .

Comparative analysis and isoform-specific therapeutic vulnerabilities of KRAS mutations in non-small cell lung cancer.

A. Redig, P. Jänne, D. Santamaría, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.

A. Redig, P. Jänne, M. Eck, 2017, Cancer research.

Understanding familial risk of pancreatic ductal adenocarcinoma.

Nicholas J. Roberts, Raymond M. Paranal, Laura D Wood, 2024, Familial cancer.